Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune is viewed positively because, despite the negative EVO756 atopic dermatitis readout, the company still has a differentiated pipeline anchored by EVO301’s positive phase 2a data and a potentially novel IL-18 mechanism that could address a large chronic inflammatory market if later studies show deeper efficacy and clean safety. The market appears to be valuing the business on a roughly $185M cash-adjusted enterprise value with cash runway extending into 2029, which suggests downside is partially buffered while the lead asset can continue advancing and the next meaningful catalysts remain in play. In addition, EVO756 remains a viable migraine program with phase 2b topline results expected in 2027, and the emerging early pipeline across TLR7/8 agonist and STAT6 programs adds optionality that supports a constructive long-term fundamental outlook.

Evommune is viewed negatively because its investment case has deteriorated from a hoped-for dual-asset story into a single, unproven bet on EVO301 after EVO756 posted back-to-back failures, with the randomized Phase 2b atopic dermatitis study in 121 adults missing both primary and secondary endpoints at every dose and the earlier chronic spontaneous urticaria study also failing, leading to no further advancement of EVO756 in AD and no assignable value to MRGPRX2. The company remains a non-revenue-generating, clinical-stage biotech with capital constraints, substantial expected financing needs within the next few years, and likely dilution before profitability, while EVO301 still faces meaningful execution risk because the subcutaneous formulation is only in bridging work, Phase 2 dose-ranging in AD is not expected to start until mid-2027, and the asset’s value still depends on yet-unproven subcutaneous data. Competitive, regulatory, and clinical-trial risks further weaken the outlook because both migraine and AD are crowded markets, patient recruitment can delay readouts, and even encouraging early IL-18 data or biomarker signals do not offset the fact that the next major value inflection remains a fuller EVO301 IV dataset targeted for presentation this fall rather than a de-risked late-stage commercial profile.